Production of highly purified no-carrier-added Lu for radioimmunotherapy

Watanabe, Satoshi; Hashimoto, Kazuyuki; Watanabe, Shigeki; Iida, Yasuhiko*; Hanaoka, Hirofumi*; Endo, Keigo*; Ishioka, Noriko

Journal of Radioanalytical and Nuclear Chemistry, 303(1), p.935 - 940, 2015/01

https://doi.org/10.1007/s10967-014-3534-y

Production of radioactive bromine Br

Watanabe, Satoshi; Watanabe, Shigeki; Iida, Yasuhiko*; Hanaoka, Hirofumi*; Endo, Keigo*; Ishioka, Noriko

JAEA-Review 2011-043, JAEA Takasaki Annual Report 2010, P. 92, 2012/01

https://jopss.jaea.go.jp/pdfdata/JAEA-Review-2011-043.pdf

no abstracts in English

PET studies of neuroendcrine tumors by using Br--bromobenzylguanidine (Br-MBBG)

Watanabe, Shigeki; Hanaoka, Hirofumi*; Liang, J. X.*; Iida, Yasuhiko*; Watanabe, Satoshi; Endo, Keigo*; Ishioka, Noriko

JAEA-Review 2010-065, JAEA Takasaki Annual Report 2009, P. 107, 2011/01

https://jopss.jaea.go.jp/pdfdata/JAEA-Review-2010-065.pdf

Imaging and biodistribution of Her2/neu expression in non-small cell lung cancer xenografts with Cu-labeled trastuzumab PET

Paudyal, P.*; Paudyal, B.*; Hanaoka, Hirofumi*; Oriuchi, Noboru*; Iida, Yasuhiko*; Yoshioka, Hiroki*; Tominaga, Hideyuki*; Watanabe, Satoshi; Watanabe, Shigeki; Ishioka, Noriko; et al.

Cancer Science, 101(4), p.1045 - 1050, 2010/04

https://doi.org/10.1111/j.1349-7006.2010.01480.x

Production of Lu-177 capable of labeling antibodies

Watanabe, Satoshi; Hashimoto, Kazuyuki; Watanabe, Shigeki; Iida, Yasuhiko*; Hanaoka, Hirofumi*; Endo, Keigo*; Ishioka, Noriko

JAEA-Review 2009-041, JAEA Takasaki Annual Report 2008, P. 109, 2009/12

https://jopss.jaea.go.jp/pdfdata/JAEA-Review-2009-041.pdf

no abstracts in English

Evaluation of Cu-labeled DOTA--Phe-Tyr-octreotide (Cu-DOTA-TOC) for imaging somatostatin receptor-expressing tumors

Hanaoka, Hirofumi*; Tominaga, Hideyuki*; Yamada, Keiichi*; Paudyal, P.*; Iida, Yasuhiko*; Watanabe, Shigeki; Paudyal, B.*; Higuchi, Tetsuya*; Oriuchi, Noboru*; Endo, Keigo*

Annals of Nuclear Medicine, 23(6), p.559 - 567, 2009/08

https://doi.org/10.1007/s12149-009-0274-0

Nano-particle materials prepared from a synthetic antigenic sequence of enolase

Oku, Hiroyuki*; Yamada, Keiichi*; Kobayashi, Kyoko*; Katakai, Ryoichi*; Ashfaq, M.*; Hanaoka, Hirofumi*; Iida, Yasuhiko*; Endo, Keigo*; Hasegawa, Shin; Maekawa, Yasunari; et al.

Peptide Science 2008, p.439 - 442, 2009/03

Malaria is the major cause of mortality and morbidity in the tropical and subtropical regions in the world. Our previous studies have shown that a series of partial peptides of a Plasmodium falciparum enolase have antigenic reactivity against patients' sera. In this paper, we wish to report nano-encapsulation of a synthetic antigen into bioabsorbable polymer particles and their releasing studies in vitro and in vivo.

Production of Cu via the Zn(p,2p) Cu reaction and recovery of Zn target

Katabuchi, Tatsuya*; Watanabe, Satoshi; Ishioka, Noriko; Iida, Yasuhiko*; Hanaoka, Hirofumi*; Endo, Keigo*; Matsuhashi, Shimpei

Journal of Radioanalytical and Nuclear Chemistry, 277(2), p.467 - 470, 2008/08

https://doi.org/10.1007/s10967-007-7144-9

Production of radioisotopes for nuclear medicine using ion beam technology and its utilization for both therapeutic and diagnostic application in cancer

Iida, Yasuhiko*; Hanaoka, Hirofumi*; Katabuchi, Tatsuya*; Watanabe, Satoshi; Ishioka, Noriko; Matsuhashi, Shimpei; Oriuchi, Noboru*; Higuchi, Tetsuya*; Miyakubo, Mitsuyuki*; Endo, Keigo*

JAEA-Review 2006-042, JAEA Takasaki Annual Report 2005, P. 165, 2007/02

https://jopss.jaea.go.jp/pdfdata/JAEA-Review-2006-042.pdf

Design, synthesis, and evaluation of [Re]Organorhenium-labeled antibody fragments with renal enzyme-cleavable linkage for low renal radioactivity levels

Uehara, Tomoya*; Koike, Miho*; Nakata, Hideo*; Hanaoka, Hirofumi*; Iida, Yasuhiko*; Hashimoto, Kazuyuki; Akizawa, Hiromichi*; Endo, Keigo*; Arano, Yasushi*

Bioconjugate Chemistry, 18(1), p.190 - 198, 2007/01

https://doi.org/10.1021/bc0602329

Renal localization of radiolabeled antibody fragments constitutes a problem in targeted imaging and radiotherapy. To estimate the applicability of the molecular design to metallic radionuclides, [Re]tricarbonyl(cyclopentadienylcarbonate)rhenium ([Re]CpTR-COOH) was conjugated with maleoyl-glycyl-lysine to prepare [Re]CpTR-GK. The cleavage of the glycyl-lysine linkage of the compound generates a glycine conjugate of [Re]CpTR-Gly. [Re]CpTR-GK was conjugated to thiolated Fab fragments to prepare [Re]CpTR-GK-Fab. The biodistribution of radioactivity after injection of [Re]CpTR-GK-Fab was compared with that of [Re]CpTR-Fab. [Re]CpTR-GK-Fab exhibited significantly lower renal radioactivity levels than did [Re]CpTR-Fab. The analysis of urine samples collected for 6 h postinjection of [Re]CpTR-GK-Fab showed that [Re]CpTR-Gly was the major radiometabolite. In tumor-bearing mice, [Re]CpTR-GK-Fab significantly reduced renal radioactivity levels without impairing the radioactivity levels in tumor. These findings indicate that the molecular design of radioparmaceuticals labeled with metallic radionuclides can be useful by using a radiometal chelate of high inertness and by designing a radiometabolite of high urinary excretion when released from antibody fragments following cleavage of a glycyl-lysine linkage. This study also indicates that a change in chemical structure of a radiolabel attached to a glycyl-lysine linkage significantly affected enzymes involved in the hydrolysis reaction.